Display options
Cite
Taylor-King JP. Rethinking rare disease: longevity-enhancing drug targets through X-linked aneuploidy. Trends Genet. 2021;doi: 10.1016/j.tig.2021.10.006.
Taylor-King, J. P. (2021). Rethinking rare disease: longevity-enhancing drug targets through X-linked aneuploidy. Trends in genetics : TIG, . https://doi.org/10.1016/j.tig.2021.10.006
Taylor-King, Jake P. "Rethinking rare disease: longevity-enhancing drug targets through X-linked aneuploidy." Trends in genetics : TIG vol. (2021). doi: https://doi.org/10.1016/j.tig.2021.10.006
Taylor-King JP. Rethinking rare disease: longevity-enhancing drug targets through X-linked aneuploidy. Trends Genet. 2021 Oct 23; doi: 10.1016/j.tig.2021.10.006. Epub 2021 Oct 23. PMID: 34702579.
Copy Download .nbib Format: NLM
Share it on

Trends Genet. 2021 Oct 23; doi: 10.1016/j.tig.2021.10.006. Epub 2021 Oct 23.

Rethinking rare disease: longevity-enhancing drug targets through X-linked aneuploidy.

Trends in genetics : TIG

Jake P Taylor-King

Affiliations

  1. Relation Therapeutics, London, UK; Juvenescence Ltd., London, UK. Electronic address: [email protected].

PMID: 34702579 DOI: 10.1016/j.tig.2021.10.006

Abstract

Complex diseases, including ageing, often exhibit sexual dimorphism. These sex differences can obfuscate attribution to causal genes within a target ID campaign. Mendelian randomisation (MR)-inspired analysis provides a natural setting to incorporate X-linked aneuploid populations, resulting in prioritisation of longevity-enhancing drug targets and motivating greater inclusion of said populations in future profiling studies.

Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords: aneuploidy; drug discovery; rare disease; target identification

Conflict of interest statement

Declaration of interests No interests are declared.

Publication Types